Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Need fast cash? Discover various ways to make fast money without breaking the law and start earning legally.
23,390 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A trio of income funds approaches yields in very different ways, highlighting a key question for retirees: how much u...
Craig Newmark is pledging to donate the bulk of his fortune, about $450 million, to issues such as misinformation and...
As the partial government shutdown stretches into weeks, houston airport, with nearly 40% TSA absences, becomes a foc...
Magnolia (MGY) is delivering a pivotal Q1 2026 performance that tests the durability of its business model. This arti...
Institutional moves can reshape a niche tech stock overnight. This article breaks down the recent liquidation by Loun...
Investors poured into Ripple ETFs at the strongest pace in months, pushing cumulative inflows toward new records. Yet...
Big bet shifts by billionaire Michael Platt grab headlines as AI giants face moves from a prominent hedge fund. This ...
As markets wobble in 2026, wealthy retirees are accelerating Roth conversions to minimize taxes and control when inco...
A focused AI tilt ETF called CHAT can outperform broad tech in some periods, but XLK’s lower fees often matter more f...
The S&P 500 endured a 14-year stretch of flat nominal growth while inflation ate away buying power, resulting in a 40...
A renowned market thinker known for optimism outlines a three-phase market path, warning of a near-term correction or...